{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:23:37Z","timestamp":1792074217986,"version":"4.4.0"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2020.00191","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T11:41:44Z","timestamp":1587037304000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":460,"title":["Metformin and Its Benefits for Various Diseases"],"prefix":"10.3389","volume":"11","author":[{"given":"Ziquan","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1146\/annurev.pa.05.040165.001055","article-title":"Pharmacology and mode of action of the hypoglycaemic sulphonylureas and diguanides","volume":"5","author":"Duncan","year":"1965","journal-title":"Annu Rev Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1172\/JCI14178","article-title":"The blooming of the French lilac","volume":"108","author":"Witters","year":"2001","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ph9020024","article-title":"Unexploited antineo plastic effects of commercially available anti-diabetic drugs","volume":"9","author":"Papanagnou","year":"2016","journal-title":"Pharmaceuticals"},{"key":"B5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s12325-018-0694-0","article-title":"Combination glucose-lowering therapy plans in T2DM: case-based considerations","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1158\/1940-6207.CAPR-13-0424","article-title":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","volume":"7","author":"Gandini","year":"2014","journal-title":"Cancer Prev Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-med-062613-093128","article-title":"Metformin in cancer treatment and prevention","volume":"66","author":"Morales","year":"2015","journal-title":"Annu Rev Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1463-1326.2010.01349.x","article-title":"Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials","volume":"13","author":"Lamanna","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.4254\/wjh.v7.i12.1652","article-title":"Systematic review: preventive and therapeutic applications of metformin in liver disease","volume":"7","author":"Bhat","year":"2015","journal-title":"World J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1111\/dom.13362","article-title":"Metformin targets brown adipose tissue in vivo and reduces oxygen consumption in vitro","volume":"20","author":"Breining","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S2213-8587(13)70125-6","article-title":"Diabetes drugs and neurological disorders: new views and therapeutic possibilities","volume":"2","author":"Patrone","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.kint.2018.01.027","article-title":"Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder","volume":"94","author":"Neven","year":"2018","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10863-006-9003-8","article-title":"The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin","volume":"38","author":"Batandier","year":"2006","journal-title":"J Bioenerg Biomembr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1042\/CS20110386","article-title":"Cellular and molecular mechanisms of metformin: an overview","volume":"122","author":"Viollet","year":"2012","journal-title":"Clin Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1042\/BJ20150497","article-title":"Repurposing metformin: an old drug with new tricks in its binding pockets","volume":"471","author":"Pryor","year":"2015","journal-title":"Biochem J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmet.2016.09.003","article-title":"Metformin activates AMPK through the lysosomal pathway","volume":"24","author":"Zhang","year":"2016","journal-title":"Cell Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrm3311","article-title":"AMPK: a nutrient and energy sensor that maintains energy homeostasis","volume":"13","author":"Hardie","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.cmet.2017.10.009","article-title":"AMPK: sensing glucose as well as cellular energy status","volume":"27","author":"Lin","year":"2018","journal-title":"Cell Metab"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2012.42.1677","article-title":"Metformin: a diabetes drug for cancer, or a cancer drug for diabetics?","volume":"30","author":"Martin","year":"2012","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.cell.2018.09.050","article-title":"Changes of cell biochemical states are revealed in protein homomeric complex dynamics","volume":"175","author":"Stynen","year":"2018","journal-title":"Cell."},{"key":"B22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1056\/NEJM199508313330902","article-title":"Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group","volume":"333","author":"Defronzo","year":"1995","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0002-9343(97)00254-4","article-title":"Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial","volume":"103","author":"Garber","year":"1997","journal-title":"Am J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1046\/j.1464-5491.2001.00582.x","article-title":"Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients","volume":"18","author":"Charpentier","year":"2001","journal-title":"Diabet Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1001\/jama.283.13.1695","article-title":"Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"283","author":"Fonseca","year":"2000","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2337\/dc15-1736","article-title":"Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naive type 2 diabetes","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2337\/dc16-1347","article-title":"Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial","volume":"40","author":"Softeland","year":"2017","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.7326\/0003-4819-130-5-199903020-00002","article-title":"Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial","volume":"130","author":"Yki-Jarvinen","year":"1999","journal-title":"Ann Intern Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.2337\/diacare.25.12.2133","article-title":"Combination of insulin and metformin in the treatment of type 2 diabetes","volume":"25","author":"Wulffele","year":"2002","journal-title":"Diabetes Care"},{"key":"B31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3389\/fnagi.2018.00322","article-title":"Evaluation of metformin on cognitive improvement in patients with non-dementia vascular cognitive impairment and abnormal glucose metabolism","volume":"10","author":"Lin","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.fertnstert.2019.09.011","article-title":"Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial","volume":"113","author":"Li","year":"2019","journal-title":"Fertil Steril"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1056\/NEJMoa0707193","article-title":"Metformin versus insulin for the treatment of gestational diabetes","volume":"358","author":"Rowan","year":"2008","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e000456","DOI":"10.1136\/bmjdrc-2017-000456","article-title":"Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age","volume":"6","author":"Rowan","year":"2018","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B35","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.cmet.2018.11.012","article-title":"A gut feeling for metformin","volume":"28","author":"Cherney","year":"2018","journal-title":"Cell Metab"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1126\/science.1120781","article-title":"The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin","volume":"310","author":"Shaw","year":"2005","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/nm.3372","article-title":"Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin","volume":"19","author":"Fullerton","year":"2013","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1172\/JCI40671","article-title":"Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1\/AMPK pathway via a decrease in hepatic energy state","volume":"120","author":"Foretz","year":"2010","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature13270","article-title":"Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase","volume":"510","author":"Madiraju","year":"2014","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cell.2009.03.016","article-title":"Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein","volume":"137","author":"He","year":"2009","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/35093131","article-title":"CREB regulates hepatic gluconeogenesis through the coactivator PGC-1","volume":"413","author":"Herzig","year":"2001","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cmet.2016.12.009","article-title":"Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex","volume":"25","author":"Howell","year":"2017","journal-title":"Cell Metab"},{"key":"B43","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nature11808","article-title":"Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP","volume":"494","author":"Miller","year":"2013","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41591-018-0159-7","article-title":"Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase","volume":"24","author":"Hunter","year":"2018","journal-title":"Nat Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1210\/jc.2002-021394","article-title":"Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2","volume":"88","author":"Gunton","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","first-page":"E1099","DOI":"10.1152\/ajpendo.00417.2013","article-title":"Two weeks of metformin treatment induces AMPK-dependent enhancement of insulin-stimulated glucose uptake in mouse soleus muscle","volume":"306","author":"Kristensen","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0126704","DOI":"10.1371\/journal.pone.0126704","article-title":"Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis","volume":"10","author":"Gu","year":"2015","journal-title":"PLoS ONE."},{"key":"B48","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature11450","article-title":"A metagenome-wide association study of gut microbiota in type 2 diabetes","volume":"490","author":"Qin","year":"2012","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature12198","article-title":"Gut metagenome in European women with normal, impaired and diabetic glucose control","volume":"498","author":"Karlsson","year":"2013","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nm.4345","article-title":"Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug","volume":"23","author":"Wu","year":"2017","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"170","DOI":"10.5604\/01.3001.0010.3801","article-title":"Metformin - its potential anti-cancer and anti-aging effects","volume":"71","author":"Podhorecka","year":"2017","journal-title":"Postepy Hig Med Dosw"},{"key":"B53","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","article-title":"AMPK phosphorylation of raptor mediates a metabolic checkpoint","volume":"30","author":"Gwinn","year":"2008","journal-title":"Mol Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/978-1-4939-0956-8_7","article-title":"G protein-coupled receptor accessory proteins and signaling: pharmacogenomic insights","volume":"1175","author":"Thompson","year":"2014","journal-title":"Methods Mol Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"6539","DOI":"10.1158\/0008-5472.CAN-09-0418","article-title":"Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth","volume":"69","author":"Kisfalvi","year":"2009","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/science.1905840","article-title":"p53 mutations in human cancers","volume":"253","author":"Hollstein","year":"1991","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-12-1226-T","article-title":"Metformin blocks melanoma invasion and metastasis development in AMPK\/p53-dependent manner","volume":"12","author":"Cerezo","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"B58","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"B59","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.cmet.2010.03.014","article-title":"Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner","volume":"11","author":"Kalender","year":"2010","journal-title":"Cell Metab"},{"key":"B60","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/1940-6207.CAPR-11-0536","article-title":"Metformin reduces endogenous reactive oxygen species and associated DNA damage","volume":"5","author":"Algire","year":"2012","journal-title":"Cancer Prev Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.semcdb.2019.05.010","article-title":"The multifaceted effects of metformin on tumor microenvironment","volume":"98","author":"Kurelac","year":"2019","journal-title":"Semin Cell Dev Biol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1021\/acs.molpharmaceut.5b00577","article-title":"Metformin: a novel but controversial drug in cancer prevention and treatment","volume":"12","author":"Sui","year":"2015","journal-title":"Mol Pharm"},{"key":"B63","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/acel.12075","article-title":"Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK\/NF-kappaB activation","volume":"12","author":"Moiseeva","year":"2013","journal-title":"Aging Cell"},{"key":"B64","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/ncomms1859","article-title":"Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC","volume":"3","author":"Blandino","year":"2012","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ccell.2019.03.007","article-title":"Combination of hypoglycemia and metformin impairs tumor metabolic plasticity and growth by modulating the PP2A-GSK3beta-MCL-1 Axis","volume":"35","author":"Elgendy","year":"2019","journal-title":"Cancer Cell."},{"key":"B66","doi-asserted-by":"publisher","first-page":"8215","DOI":"10.1073\/pnas.0708100105","article-title":"Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy","volume":"105","author":"Raffaghello","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B67","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12013-014-0459-6","article-title":"Breast cancer: epidemiology and etiology","volume":"72","author":"Tao","year":"2015","journal-title":"Cell Biochem Biophys"},{"key":"B68","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3978\/j.issn.2305-5839.2014.06.01","article-title":"Metformin in cancer prevention and therapy","volume":"2","author":"Kasznicki","year":"2014","journal-title":"Ann Transl Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"6962","DOI":"10.1128\/MCB.02415-06","article-title":"Heme induces ubiquitination and degradation of the transcription factor Bach1","volume":"27","author":"Zenke-Kawasaki","year":"2007","journal-title":"Mol Cell Biol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41586-019-1005-x","article-title":"Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism","volume":"568","author":"Lee","year":"2019","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1517\/14728222.2014.924507","article-title":"AKT as a therapeutic target in multiple myeloma","volume":"18","author":"Keane","year":"2014","journal-title":"Expert Opin Ther Targets."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1038\/leu.2015.157","article-title":"Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib","volume":"29","author":"Jagannathan","year":"2015","journal-title":"Leukemia"},{"key":"B74","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1182\/blood-2011-07-366203","article-title":"The PI3K\/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia","volume":"119","author":"Polak","year":"2012","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1038\/cddis.2012.13","article-title":"Therapeutic metformin\/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy","volume":"3","author":"Shi","year":"2012","journal-title":"Cell Death Dis"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1053\/j.gastro.2004.07.011","article-title":"Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients","volume":"127","author":"Yang","year":"2004","journal-title":"Gastroenterology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.2337\/dc11-0512","article-title":"Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis","volume":"34","author":"Zhang","year":"2011","journal-title":"Diabetes Care"},{"key":"B78","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","article-title":"Metformin and the gastrointestinal tract","volume":"59","author":"Mccreight","year":"2016","journal-title":"Diabetologia"},{"key":"B79","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ygyno.2013.11.021","article-title":"Metformin is associated with improved survival in endometrial cancer","volume":"132","author":"Ko","year":"2014","journal-title":"Gynecol Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11864-006-0011-z","article-title":"Epidemiology and prevention of cutaneous melanoma","volume":"7","author":"Demierre","year":"2006","journal-title":"Curr Treat Options Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","article-title":"Cutaneous melanoma","volume":"383","author":"Eggermont","year":"2014","journal-title":"Lancet"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1038\/s41388-018-0172-9","article-title":"Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression","volume":"37","author":"Li","year":"2018","journal-title":"Oncogene"},{"key":"B84","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.pedn.2012.02.001","article-title":"The use of simulation for pediatric oncology nursing safety principles: ensuring competent practice through the use of a mnemonic, chemotherapy road maps and case-based learning","volume":"27","author":"Linnard-Palmer","year":"2012","journal-title":"J Pediatr Nurs"},{"key":"B85","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"B86","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.bone.2010.08.001","article-title":"AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts","volume":"47","author":"Lee","year":"2010","journal-title":"Bone"},{"key":"B87","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nature05488","article-title":"Abdominal obesity and metabolic syndrome","volume":"444","author":"Despres","year":"2006","journal-title":"Nature"},{"key":"B88","doi-asserted-by":"publisher","first-page":"5813030","DOI":"10.1155\/2016\/5813030","article-title":"Metformin prevents fatty liver and improves balance of white\/brown adipose in an obesity mouse model by inducing FGF21","volume":"2016","author":"Kim","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.biopha.2019.01.021","article-title":"Metformin enhances mitochondrial biogenesis and thermogenesis in brown adipocytes of mice","volume":"111","author":"Karise","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"B90","doi-asserted-by":"publisher","first-page":"14405","DOI":"10.1038\/srep14405","article-title":"Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci Rep"},{"key":"B91","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/ajg.2013.5","article-title":"Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"108","author":"Singh","year":"2013","journal-title":"Am J Gastroenterol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/79697","article-title":"Metformin reverses fatty liver disease in obese, leptin-deficient mice","volume":"6","author":"Lin","year":"2000","journal-title":"Nat Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2337\/diabetes.53.8.2169","article-title":"Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes","volume":"53","author":"Tiikkainen","year":"2004","journal-title":"Diabetes"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1345\/aph.1P099","article-title":"Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease","volume":"44","author":"Cone","year":"2010","journal-title":"Ann Pharmacother"},{"key":"B96","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nrd.2015.3","article-title":"Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies","volume":"15","author":"Musso","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/S0140-6736(19)30541-0","article-title":"The rise and fall of aspirin in the primary prevention of cardiovascular disease","volume":"393","author":"Raber","year":"2019","journal-title":"Lancet"},{"key":"B98","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/osp4.309","article-title":"A systematic review: the appraisal of the effects of metformin on lipoprotein modification and function","volume":"5","author":"Kheniser","year":"2019","journal-title":"Obes Sci Pract"},{"key":"B99","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ihj.2017.05.009","article-title":"Metformin in heart failure patients","volume":"70","author":"Kinsara","year":"2018","journal-title":"Indian Heart J"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.3390\/ijms19102869","article-title":"Metabolic effects of metformin in the failing heart","volume":"19","author":"Dziubak","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B101","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1093\/eurheartj\/ehz203","article-title":"A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial","volume":"40","author":"Mohan","year":"2019","journal-title":"Eur Heart J"},{"key":"B102","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1126\/science.1172539","article-title":"Extending healthy life span\u2013from yeast to humans","volume":"328","author":"Fontana","year":"2010","journal-title":"Science"},{"key":"B103","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/CIRCRESAHA.116.309622","article-title":"New definition of aging? Measuring regenerative capacity in patients","volume":"119","author":"Losordo","year":"2016","journal-title":"Circ Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMra0804615","article-title":"DNA damage, aging, and cancer","volume":"361","author":"Hoeijmakers","year":"2009","journal-title":"N Engl J Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cell.2011.07.030","article-title":"Autophagy and aging","volume":"146","author":"Rubinsztein","year":"2011","journal-title":"Cell"},{"key":"B106","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"B107","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/1440-1681.12265","article-title":"Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus","volume":"41","author":"Guo","year":"2014","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1007\/s00125-017-4349-5","article-title":"Metformin and ageing: improving ageing outcomes beyond glycaemic control","volume":"60","author":"Valencia","year":"2017","journal-title":"Diabetologia"},{"key":"B109","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4161\/15548627.2014.984271","article-title":"Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway","volume":"11","author":"Song","year":"2015","journal-title":"Autophagy"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cmet.2016.05.011","article-title":"Metformin as a tool to target aging","volume":"23","author":"Barzilai","year":"2016","journal-title":"Cell Metab"},{"key":"B111","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/ki.2012.208","article-title":"Acute kidney injury and chronic kidney disease: an integrated clinical syndrome","volume":"82","author":"Chawla","year":"2012","journal-title":"Kidney Int"},{"key":"B112","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1056\/NEJM199801223380415","article-title":"Lactic acidosis in patients with diabetes treated with metformin","volume":"338","author":"Misbin","year":"1998","journal-title":"N Engl J Med"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1681\/ASN.2018010050","article-title":"Phosphorylation of Acetyl-CoA Carboxylase by AMPK Reduces Renal Fibrosis and Is Essential for the Anti-Fibrotic Effect of Metformin","volume":"29","author":"Lee","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12882-017-0579-5","article-title":"Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study","volume":"18","author":"Bell","year":"2017","journal-title":"BMC Nephrol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00191\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T11:42:44Z","timestamp":1587037364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00191\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":114,"alternative-id":["10.3389\/fendo.2020.00191"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.00191","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,16]]},"article-number":"191"}}